Confidential · GrubClub · Rohan Kalani
by GrubClub · Made in India

Prosem

Light. Clear. Gone in 2 Sips.

A featherweight 100ml daily shot with 15g easily digestible clear whey protein, 3g prebiotic fibre, and immunity-boosting amla + ginger — designed for patients on GLP-1 therapy whose gut can’t handle anything heavy.

15g Light Protein 3g Prebiotic Fibre Amla Immunity Ginger Anti-Nausea 100ml — Not a Shake
Prosem Daily Shot — protein, ginger, fibre
Why Prosem

The Lightest Way to Get Your Protein, Fibre & Immunity

GLP-1 drugs like Semaglutide slow your gut and kill your appetite. Heavy shakes sit like a brick. Meals feel impossible. Prosem is engineered to be the opposite — ultralight, fast-absorbing, gone before your stomach notices.

15g
Clear Whey Protein
Not casein. Not plant sludge. Clear whey isolate — the fastest-digesting protein that exists. Preserves lean muscle without the heaviness. Like drinking water, not cement.
3g
Prebiotic Soluble Fibre
Inulin + SCF — dissolves completely in liquid, zero grit, zero bloating. Feeds your gut microbiome, relieves the constipation that 44% of GLP-1 patients suffer.
750mg
Amla + Ginger Immunity
500mg amla (Vitamin C + antioxidants, Ayurvedic heritage) + 250mg ginger extract (clinically proven anti-emetic). Immunity support when your body is running on empty.
Prosem protein fibre ginger
Why “clear” matters: Traditional whey shakes are thick, milky, and sit in a slowed GLP-1 stomach for hours. Clear whey isolate has the protein without the casein — it passes through fast, absorbs fast, and doesn’t trigger the nausea that thick liquids cause. This is why Prosem works when nothing else will.
Prosem vs Thick Protein Shakes
  • 100ml clear liquid vs 300–500ml thick shake
  • Fast gastric transit vs sits for hours
  • Zero bloating vs heavy, gassy feeling
  • Warm ginger flavour vs artificial sweetness
  • Consumed in 2 sips vs forced to finish
March 2026

India’s GLP-1 Wave Just Hit

Semaglutide patent expired March 20, 2026. 40+ Indian generics launched in 48 hours. Price crashed from ₹11,000 to ₹1,290/month. Millions of new patients are coming — and none of them have nutritional support.

90M
Indians with diabetes (IDF 2025)
254M
Adults with obesity (ICMR 2025)
177%
Semaglutide growth YoY
40+
Generic brands in week 1
The trigger: At ₹1,290–4,200/month (vs ₹11,000 before), Semaglutide becomes accessible to India’s massive population. Dr. Reddy’s alone plans 12 million pens in Year 1. Every patient will face protein deficiency, constipation, and nausea. Prosem is the answer.
The Problem

GLP-1 Works. But Patients Suffer.

Semaglutide suppresses appetite so effectively that patients can’t meet basic nutritional needs. This is not a side effect — it’s a treatment-limiting crisis.

Muscle Loss
40%
of weight lost on GLP-1 can be lean muscle — patients lose the wrong weight, get weaker, face metabolic slowdown
Constipation
44%
report persistent constipation from slowed gastric emptying — drives discomfort and treatment abandonment
Nausea + Drop-off
30–50%
discontinue GLP-1 therapy within 12 months — nausea and food aversion create a vicious cycle

No Indian clinical guideline on nutrition support during GLP-1 therapy exists yet.
This is a white space. We fill it.

Prosem lifestyle
The Solution

2–3 Sips. Full Daily Compliance.

Prosem is a 100ml clear liquid shot — not a shake, not a meal. Warm, ginger-forward, designed for stomachs that don’t want anything.

  • 15g Clear Whey Protein Isolate — preserves lean muscle mass
  • 3g Soluble Fibre (Inulin/SCF) — relieves constipation without bloating
  • 500mg Amla (Nellikka) Extract — antioxidant + gut health
  • 250mg Ginger Extract — clinically proven to reduce nausea
  • Low Osmolarity Formula — easy on a slowed gut
Formulation

Every Ingredient Earns Its Place

Designed with Indian endocrinologists. Rooted in Ayurvedic wisdom. Backed by clinical evidence.

15g
Clear Whey Isolate
Prevents sarcopenia from caloric deficit
3g
Soluble Fibre
Inulin + SCF — prebiotic effect
500mg
Amla Extract
Indian gooseberry — Vitamin C + digestive aid
250mg
Ginger Extract
Anti-emetic — proven nausea reduction
Natural ingredients
Why this format wins: Clear liquid → fast gastric transit (unlike thick shakes). 100ml volume → requires zero appetite. Low osmolarity → minimal GI distress. Shot format → consumed like medicine, not food. Warm ginger flavour → familiar to Indian palates.
For Clinicians

Prescribe Compliance. Not Just a Drug.

India has ~2,200 registered endocrinologists for 90 million diabetics. Your time with each patient is limited. Prosem gives you a compliance tool that works when you’re not in the room.

  • 7-day starter pack for new GLP-1 prescriptions
  • 30-day GLP-1 Support Kit for ongoing patients
  • 20–25% clinic margin — zero inventory burden
  • Direct-to-patient delivery after clinic trial
  • FSSAI compliant — Health Supplement category
Doctor consultation
Plans

Start With Your Doctor. Continue at Home.

Doctor-prescribed trial → patient subscription → delivered to your door.

7-Day Trial
₹840
Clinic starter pack
7 daily shots
₹120 per shot
Doctor-initiated
Try before you subscribe
Monthly
₹2,999
per month, delivered
30 daily shots
₹100 per shot
Free doorstep delivery
Pause or cancel anytime
Quarterly
₹7,999
every 3 months
90 daily shots
₹89 per shot
Free delivery
Save 26%
Less than the cost of a daily chai. More impact than any meal you’re skipping.

We’re Not Selling a Drink.
We’re Ensuring Patients Stay on Treatment.

Launching with endocrinology and bariatric clinics in Bangalore, Kochi, and Chennai.

Prosem · prosem.kalanitech.co

GrubClub · Investor Deck

Prosem

The Default Nutrition Protocol for GLP-1 Therapy in India.

100ml daily shot. Doctor-prescribed. Patient-subscribed.
Clinical nutrition compliance in 2–3 sips.

Confidential · GrubClub · Rohan Kalani

Why Now

India’s Semaglutide Patent Expired on March 20, 2026

The dam broke. 40+ generic brands launched in 48 hours. Prices crashed 97%. India’s GLP-1 market will 5x to ₹5,000 crore by 2030.

Novo Nordisk (Ozempic/Wegovy) ₹11,000/mo
₹11,000
Dr. Reddy’s (Obeda) ₹4,200/mo
₹4,200
Zydus (Semaglyn) ₹2,200/mo
₹2,200
Natco/Eris (lowest) ₹1,290/mo
₹1,290
₹1,446 Cr
Semaglutide MAT (Feb 2026) — up 177% YoY
₹5,000 Cr
Projected GLP-1 market by 2030 (CareEdge)
12M
Injectable pens Dr. Reddy’s plans to sell in Year 1
The math: India has 90M diabetics + 254M obese adults. GLP-1 is currently only 5% of the anti-diabetes market by value. With 40+ generic brands at ₹1,290–4,200/month, penetration will surge 5–10x. Every new patient needs nutritional support. Nobody is providing it.
The Problem

Predictable Side Effects. Zero Nutritional Solutions.

1. Protein Deficiency → Muscle Loss
Up to 40% of weight lost is lean muscle (SELECT, SURMOUNT trials). Indian patients — already at higher risk for the “skinny-fat” phenotype (ICMR: only 26.6% of Indian adults are metabolically healthy) — lose the wrong weight.
2. Constipation → Drop-off
44% of patients report persistent constipation. Indian vegetarian diets already have variable fibre intake. GLP-1’s slowed gastric motility makes this worse.
3. Nausea Cycle
50%+ experience nausea during dose titration. The less they eat, the worse they feel. The worse they feel, the less they eat. 30–50% discontinue within 12 months.
Zero

Indian clinical guidelines on nutrition during GLP-1 therapy

The white space: No RSSDI or API guideline exists. No Indian RCT on protein/micronutrient needs during Semaglutide therapy. Sun Pharma launched a “holistic patient support program” alongside their generic — the market knows this gap exists. No one has filled it.
Clinical mechanism
The Solution

Prosem: Treatment Support, Not a Beverage

100ml clear liquid daily shot. Warm ginger-forward flavour. Consumed in 2–3 sips. Even with zero appetite.

15g
Clear Whey Isolate
Preserves lean muscle mass
3g
Soluble Fibre
Inulin + SCF — relieves constipation
500mg
Amla Extract
Vitamin C + gut health (Ayurvedic heritage)
250mg
Ginger Extract
Clinically proven anti-emetic
Why This Format Wins in India
  • Clear liquid → fast gastric transit (unlike Ensure/Resource shakes)
  • 100ml volume → requires zero appetite to finish
  • Warm ginger + amla → familiar Indian palate, not foreign taste
  • Shot format → consumed like kadha, not food
  • ₹89–120/day → less than a daily chai at a restaurant
Prosem product
Business Model

Doctor-Led Distribution + Patient Subscription

Acquisition: In Clinics
Endocrinologist prescribes Prosem alongside GLP-1 therapy. Patient starts with 7-day trial pack (₹840). Part of their treatment protocol — zero friction. CDSCO banned direct GLP-1 advertising (March 2026) — the doctor IS the only channel.
Retention: Subscription
After trial, patients subscribe (₹2,999/mo). Delivered to their door via 3PL. Pause or cancel anytime. No clinic visit for refill. Duration matches GLP-1 therapy: 6–12+ months.
Doctors prescribe → Patients subscribe → We retain.
CAC is near-zero: the doctor IS the distribution channel. CDSCO’s advertising ban makes doctor-led distribution the only viable go-to-market for GLP-1 adjacent products.

Unit Economics

COGS per shot ₹40–50
MRP per shot ₹120–140
Gross Margin 60%+
Monthly Subscription ₹2,999
Doctor Margin 20–25%
Patient Lifetime (avg) 6–12 months
₹18K–36K

LTV per patient

Go-To-Market

South India First. Then National. Then GCC.

Phase 1 — Q3 2026
Pilot: 5 Clinics in Bangalore + Kochi

Endocrinology + bariatric clinics. 30-day cohorts. Target: 80% trial-to-subscription conversion. Karnataka has 233 registered endocrinologists.

Phase 2 — Q4 2026
Scale: 50 Clinics in South India

Bangalore, Chennai, Kochi, Hyderabad. Medical rep partnerships. Apollo, Fortis network access. Subscription delivery via 3PL.

Phase 3 — 2027
National: 500+ Clinics + D2C

Pan-India. Mumbai (Maharashtra: 325 endocrinologists), Delhi, Kolkata. Pharmacy partnerships: Apollo Pharmacy, MedPlus, PharmEasy.

Phase 4 — 2028
GCC + Southeast Asia

Dubai, Singapore, Thailand — GLP-1 adoption surging. Same doctor-led model. Local manufacturing partners.

India clinic
Clinic Economics
Doctor margin/subscription ₹600–750/mo
25%
Patient compliance target 85%
85%
Inventory risk for clinic Zero
0
Competitive Advantage

Four Moats. Not One.

01
Purpose-Built Formulation
Not a rebranded protein shake. Every ingredient, concentration, osmolarity, and volume is designed for GLP-1 physiology. Amla + ginger roots it in Indian clinical tradition. No off-the-shelf product addresses all three side effects.
02
Doctor Distribution Lock-In
CDSCO banned direct GLP-1 advertising (March 2026). The only channel is the doctor. Once embedded in clinical protocol, switching costs are high. Our clinic relationships ARE the moat.
03
Subscription Retention
Patients subscribe for the duration of GLP-1 therapy (6–12+ months). It’s prescribed nutritional support, not a discretionary purchase. At ₹100/day, it’s cheaper than the food they’re replacing.
04
Clinical Data Flywheel
Every cohort generates adherence + outcome data. No Indian RCT on GLP-1 nutrition exists. We build it. This strengthens doctor confidence, improves formulation, and becomes the basis for RSSDI guideline inclusion.
India Landscape

The Numbers That Matter

Patient Population
Diabetics (IDF 2025)90M
Obese adults (ICMR 2025)254M
Undiagnosed diabetics39M (43%)
Pre-diabetic136M
Metabolically unhealthy adults73%
Market Size
GLP-1 market (Feb 2026)₹1,446 Cr
Anti-obesity CAGR (3yr)61.4%
GLP-1 by 2030 (CareEdge)₹5,000 Cr
Nutraceutical market$6B+
Nutraceutical CAGR11–18%
Generic Brands (Day 1)
Dr. Reddy’s — Obeda₹4,200/mo
Sun Pharma — Noveltreat₹3,600–8K
Zydus — Semaglyn₹2,200/mo
Natco — Semanat₹1,290/mo
Eris (lowest)₹220/shot
Expected by year-end100+ brands
Regulatory
Patent expiredMar 20, 2026
CDSCO ad banMar 11, 2026
FSSAI nutraceuticalSupportive
GLP-1 nutrition guidelinesNone exist
Financials

Path to ₹10 Cr ARR by 2028

Year 1 — Pilot
200
Subscribers
₹72L
Annual Revenue
Year 2 — Scale
1,500
Subscribers
₹5.4 Cr
Annual Revenue
Year 3 — National
5,000
Subscribers
₹18 Cr
Annual Revenue
Year 4 — International
15,000
Subscribers
₹54 Cr
Annual Revenue
Key assumptions: ₹3,000/mo avg subscription, 8-month avg lifetime, 60% gross margin, 50 clinics adding 30 patients/month by Year 2. Conservative — excludes pharmacy (Apollo, MedPlus) and D2C channel.

Use of Funds (Seed: ₹2 Cr)

R&D 35%
Sales 30%
Ops 20%
Reg 15%
R&D (₹70L): Formulation, FSSAI approval, clinical pilot, contract manufacturing
Sales (₹60L): Medical reps, clinic onboarding, trial kits, KOL events
Ops (₹40L): Manufacturing partner, packaging, 3PL delivery, subscription platform
Reg (₹30L): FSSAI licensing, clinical study, labelling, quality testing
Next Steps

Defining a New Clinical
Nutrition Category in India.

Step 1
5 clinics, 30-day cohorts
Bangalore + Kochi pilot
Step 2
Adherence + outcome data
India’s first GLP-1 nutrition study
Step 3
50 clinics + subscriptions
Doctor network + recurring revenue
Monthly subscription

We are not selling a drink.
We are ensuring patients stay on treatment — and succeed.

Prosem · GrubClub · Confidential